首页> 美国卫生研究院文献>Journal of Virology >CD8+ Lymphocytes Do Not Mediate Protection against Acute Superinfection 20 Days after Vaccination with a Live Attenuated Simian Immunodeficiency Virus
【2h】

CD8+ Lymphocytes Do Not Mediate Protection against Acute Superinfection 20 Days after Vaccination with a Live Attenuated Simian Immunodeficiency Virus

机译:接种减毒活的猿猴免疫缺陷病毒接种后20天CD8 +淋巴细胞未介导针对急性超级感染的保护作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In order to test the hypothesis that CD8+ cytotoxic T lymphocytes mediate protection against acute superinfection, we depleted >99% of CD8+ lymphocytes in live attenuated simian immunodeficiency virus macC8 (SIVmacC8) vaccinees from the onset of vaccination, maintained that depletion for 20 days, and then challenged with pathogenic, wild-type SIVmacJ5. Vaccinees received 5 mg per kg of humanized anti-CD8 monoclonal antibody (MAb) 1 h before inoculation, followed by the same dose again on days 3, 7, 10, 13, and 17. On day 13, peripheral CD8+ T lymphocytes were >99% depleted in three out of four anti-CD8 MAb-treated vaccinees. At this time attenuated SIVmacC8 viral RNA loads in anti-CD8 MAb-treated vaccinees were significantly higher than control vaccinees treated contemporaneously with nonspecific human immunoglobulin. Lymphoid tissue CD8+ T lymphocyte depletion was >99% in three out of four anti-CD8 MAb-treated vaccinees on the day of wild-type SIVmacJ5 challenge. All four control vaccinees and three out of four anti-CD8 MAb-treated vaccinees were protected against detectable superinfection with wild-type SIVmacJ5. Although superinfection with wild-type SIVmacJ5 was detected at postmortem in a single anti-CD8 MAb-treated vaccinee, this did not correlate with the degree of preceding CD8+ T lymphocyte depletion. Clearance of attenuated SIVmacC8 viremia coincided with recovery of normal CD8+ T lymphocyte counts between days 48 and 76. These results support the view that cytotoxic T lymphocytes are important for host-mediated control of SIV primary viremia but do not indicate a central role in protection against acute superinfection conferred by inoculation with live attenuated SIV.
机译:为了检验关于CD8 + 细胞毒性T淋巴细胞介导对急性超级感染的保护这一假设,我们在减毒的猿猴免疫缺陷病毒macC8(SIVmacC8)中消耗了超过99%的CD8 + 淋巴细胞。 )从接种开始就接种疫苗,将其耗竭20天,然后用致病的野生型SIVmacJ5攻击。疫苗接种前1小时,疫苗每公斤接受5 mg人源化抗CD8单克隆抗体(MAb),然后在第3、7、10、13和17天再次接种相同剂量的疫苗。在第13天,外周CD8 + 在用抗CD8单抗治疗的4种疫苗中,有3种的T淋巴细胞耗竭率超过99%。此时,抗CD8 MAb治疗的疫苗中减毒的SIVmacC8病毒RNA载量明显高于同时用非特异性人免疫球蛋白治疗的对照疫苗。在野生型SIVmacJ5攻击当天,四分之三抗CD8 MAb处理的疫苗中,三分之二的淋巴组织CD8 + T淋巴细胞耗竭率> 99%。所有四种对照疫苗和四种抗CD8 MAb治疗的疫苗中的三种均受到保护,以免被野生型SIVmacJ5感染。尽管在死后在单个抗CD8 MAb处理的疫苗中检测到野生型SIVmacJ5的过度感染,但这与先前CD8 + T淋巴细胞的耗竭程度无关。减毒的SIVmacC8病毒血症的清除与正常CD8 + T淋巴细胞计数的恢复在第48天到第76天之间吻合。这些结果支持以下观点:细胞毒性T淋巴细胞对于宿主介导的SIV原发性病毒血症的控制很重要,但确实没有表明在预防活的减毒SIV赋予的急性超感染保护中起着中心作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号